$Hepion Pharmaceuticals (HEPA.US)$ Hepion ends Phase 2 study for NASH drug due to cash restraints!
Hepion Pharmaceuticals (NASDAQ:HEPA) said it has begun winding down its ASCEND-NASH Phase 2 study for its drug rencofilstat as it continues to explore strategic alternatives for the company.
“We are disappointed to announce the wind-down of our Phase 2 NASHtr...

$Hepion Pharmaceuticals (HEPA.US)$ it got through the 200day MA lets see if it holds as support. if it test and stays above i might add some.

$Hepion Pharmaceuticals (HEPA.US)$ announced that their 2a trial findings have been published in the journal Hepatology Communications. In those findings the mention Pro-C3 reduction levels in a 28 day period that other drugs/studies take a minimum of over 3 months to achieve.
Additionally, their press release mentions that screening of patients for the 2b trial began at the end of August.

$AT&T (T.US)$
The undisputed champion of telecom!
get ready, shes coming strong.

$Amazon (AMZN.US)$ ’s retail business enjoys strong purchasing power and an unrivaled distribution network. As a result, Amazon is able to provide a very large selection of goods at very attractive prices to customers while offering a very convenient way of shopping (one-day free delivery…). Third-party sellers benefit from the attractiveness of Amazon’s marketplace. Indeed, Amazon has such a strong reputation that most consumers go directly to Amazon to start their produc...